Dasatinib

Catalog No.S1021

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Dasatinib Chemical Structure

Dasatinib Chemical Structure
Molecular Weight: 488.01

Validation & Quality Control

Cited by 62 publications:

10 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Pan Src Inhibitor

    Saracatinib (AZD0530) Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.

  • FDA-approved Src Inhibitor

    Bosutinib (SKI-606) Approved by FDA for Ph+ chronic myelogenous leukemia (CML).

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
IC50 0.6 nM 0.8 nM 37 nM 79 nM
In vitro Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jaflczKGh?M3mzS2ROW09?NFr0OFlKSzVyPUCuNFAxODdizszNNHv1bFQyPzl3NkC4NC=>
K562NYHSSoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TZWVczKGh?NVvSSYlMTE2VTx?=MXHJR|UxRTBwMECxJO69VQ>?NG\VWHQyPzl3NkC4NC=>
M07eM3Hne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrhO|IhcA>?MYfEUXNQMV\JR|UxRTBwMECxNkDPxE1?Mn7vNVc6PTZyOEC=
ALL3MnfMR5l1d3SxeHnjJGF{e2G7MnXyNE4y|ryPNGXDfnI4OiCqMlrzSG1UVw>?M{HmS2lEPTB;MD6wNFA1KM7:TR?=NUC0TVI3OTl6OEm1OFA>
CMLNUHsc|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYr6[IEyOjBibXnuMVTEUXNQMVTJR|UxRTBwMECxJO69VQ>?NHnsbZQyQTJzOUCxOi=>
BA/F3M{XuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLTO|IhcA>?MXzEUXNQMmfxTWM2OD14LkW4PUDPxE1?Mn7rNlMxQDh4NES=
BA/F3NEPqVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HwPFczKGh?NIjHR5VFVVORMorNTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2=MYCyN|A5QDZ2NB?=
BA/F3NISzOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTncoE4OiCqM1PtOmROW09?MoPhTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?MWCyN|A5QDZ2NB?=
BA/F3MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3[yT|czKGh?MWjEUXNQNVXuVJZ[UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszNMX2yN|A5QDZ2NB?=
BA/F3Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPqO|IhcA>?NHjNN2RFVVORMnPPTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1?Mn\rNlM{ODF5MEO=
BA/F3M3T0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWm3NkBpNGHaUHVFVVORNH:3UGRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?=MVSyN|MxOTdyMx?=
BA/F3MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4mweFczKGh?MYHEUXNQMUnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>?MY[yN|MxOTdyMx?=
BA/F3MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nK[FczKGh?NUPSZWtbTE2VTx?=NWDtbJNbUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=M{LXV|I{OzBzN{Cz
BA/F3M1LpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXe3NkBpNGqyUXNFVVORNFvYS4lKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?=NFrFToQzOzNyMUewNy=>
BA/F3M3jJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTXO|IhcA>?NX\SUG52TE2VTx?=NVnX[JF4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1?Mm\jNlM{ODF5MEO=
BA/F3MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rx[lczKGh?MWHEUXNQNFXFdWFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?=MYCyN|MxOTdyMx?=
BA/F3NEjWdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3VXIJnPzJiaB?=MVzEUXNQMl[xTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0>NW\EZYQyOjN|MEG3NFM>
BA/F3NGfyeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfTdIdbPzJiaB?=MWPEUXNQNEPJWGFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=MXWyN|MxOTdyMx?=
T cellMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXu3NkBpNWnnSY0zTE2VTx?=NUPySYFZUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1?MVKxO|E2PDVzMh?=
WiDrNGDiWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fOd|czKGh?MUTEUXNQM3X2bWlEPTB;MD6wOVIh|ryPMUmxOVYyPTVzMh?=
PC3M4fwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUO3NkBpNGrFS|lFVVORNYPYWJhJUUN3ME2wMlAxQTRizszNMY[xOVYyPTVzMh?=
MDA-MB-231MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzoOZM4OiCqM4DLcWROW09?MWPJR|UxRTBwMEGyJO69VQ>?M37OblE2PjF3NUGy
Hs578TNVnY[FdwS3m2b4TvfIlkKEG|c3H5MV[3NkBpNYXqZpNOTE2VTx?=MWjHTVUxRTBwMEOg{txONYDJTlNuOjRyMUWzNlc>
HMECM4DBNmN6fG:2b4jpZ{BCe3OjeR?=MYi3NkBpNYXWR|BPTE2VTx?=NWDUc2J6T0l3ME2xMlgh|ryPMnrwNlQxOTV|Mke=
DU145NVq4[mhxS3m2b4TvfIlkKEG|c3H5MVK3NkBpMX;EUXNQNFLtWWtIUTVyPUCuNVYh|ryPNIrhco8zPDBzNUOyOy=>
U251NUnKeY92S3m2b4TvfIlkKEG|c3H5M3LrPVczKGh?M3;5fmROW09?M4O5SGdKPTB;Mj64NUDPxE1?M17ZUVI1ODF3M{K3
NCI60NH7ZVWlEgXSxdH;4bYMhSXO|YYm=Ml[zO|IhcA>?MV;EUXNQMVPHTVUxRTVwNzFOwG0>MnjZNlQxOTV|Mke=
MALME-3MMmq3R5l1d3SxeHnjJGF{e2G7NWfkeYlMPzJiaB?=MX7EUXNQMXPHTVUxRTZwNkGg{txOMmHhNlQxOTV|Mke=
KM12M1SzVWN6fG:2b4jpZ{BCe3OjeR?=NFTnUlg4OiCqMYrEUXNQMl3vS2k2OD15LkS0JO69VQ>?MU[yOFAyPTN{Nx?=
SW620NFTRU|FEgXSxdH;4bYMhSXO|YYm=NXzEV3NFPzJiaB?=Mo\uSG1UVw>?NFTk[mZIUTVyPUiuOFMh|ryPM3rMcVI1ODF3M{K3
RXF 393NLMlPvR5l1d3SxeHnjJGF{e2G7NGq4O4U1KGSjeYO=MojBSG1UVw>?MmXyTWM2OD1yLkCyNVch|ryPMnf2NlMzPTNyN{S=
LXFA 983LMV\DfZRwfG:6aXOgRZN{[Xl?NUexTJFPPCCmYYnzM{ixWGROW09?NH;WUoNKSzVyPUCuNFU3PSEQvF2=M3\sdlI{OjV|MEe0
PRXF DU145M{LUT2N6fG:2b4jpZ{BCe3OjeR?=MWi0JIRigXN?NVXLblFZTE2VTx?=NEXKT5BKSzVyPUCuNFYzOyEQvF2=M1f1N|I{OjV|MEe0
PAXF 1657LM3f3XmN6fG:2b4jpZ{BCe3OjeR?=M{fGWlQh\GG7cx?=MYTEUXNQMnPETWM2OD1yLkGyNUDPxE1?NEfzRoszOzJ3M{C3OC=>
CXF 1103LM2i1emN6fG:2b4jpZ{BCe3OjeR?=NUnyU21OPCCmYYnzM{fpRWROW09?MX7JR|UxRTRwM{[g{txOMo[0NlMzPTNyN{S=
GXF251LMnP4R5l1d3SxeHnjJGF{e2G7NX3ZdHBDPCCmYYnzM3;LTmROW09?NVvzc|A2UUN3ME2yMlI2KM7:TR?=NFn5VmszOzJ3M{C3OC=>
NCI-H23MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\JNlczKGh?NXPwXXhvTE2VTx?=M3zjbWlEPTB;Mj6yO{DPxE1?MWCyN|UzOTB{MB?=
HCT116M1K1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\5O|IhcA>?MnGwSG1UVw>?M2D4UmlEPTB;Mj6zJO69VQ>?MXyyN|UzOTB{MB?=
MCF7NV64NlZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jqfVczKGh?NH;3d2NFVVORNHe0TYlKSzVyPUKuOVch|ryPNFXH[FczOzV{MUCyNC=>
NCI-H460NVOzVpJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPjVWY4OiCqNHHuOmVFVVORM1X6RmlEPTB;OD65PUDPxE1?MoHmNlM2OjFyMkC=
DLD1M3P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\oT5JCPzJiaB?=NGXEUHJFVVORNVPjW3J6UUN3ME20MlYh|ryPNFfmRpEzOzV4N{m2NC=>
NCI-H661NFS0OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrUO|IhcA>?MlnTSG1UVw>?M{WzPGlEPTB;Nz64JO69VQ>?NF3FV4EzOzV4N{m2NC=>
A549Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPDXIJ3PzJiaB?=NUTGe41sTE2VTx?=MY\JR|UxRThwMjFOwG0>MVeyN|U3Pzl4MB?=
U937MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfKNVF{PzJiaB?=MYnEUXNQMYfJR|UxRTF{LkKg{txONUXBXm5bOjN3Nke5OlA>
HEK293NITpPXVHfW6ldHnvckBCe3OjeR?=NGHxXVIyOMLizszNMVjEUXNQNGfZWJlKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=>M37NWFIzPzdyNkGw
HUVECMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPFNE4yPcLizszNNGjuZ404OiCqNEG3OlJFVVORMV7JcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2=NI\ZTZczOjh3M{m5Ny=>
HUVECM33TbGZ2dmO2aX;uJGF{e2G7MV[xOeKh|ryPMoDLO|IhcA>?M4nVR2ROW09?NHGzOZBKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>?NWe0cZdxOjJ6NUO5PVM>
Plasmodium falciparumMXjGeY5kfGmxbjDBd5NigQ>?M4D3S|ExyqEQvF2=Ml\tNVUhdWmwMl[0SG1UVw>?MlP2TY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txOMW[yOFU2ODN|MB?=
PC3NGHoU49HfW6ldHnvckBCe3OjeR?=NYju[nd2OC5zIN88US=>MV:1JIg>NFPHbXlFVVORNFH0S5dKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2=NWLMTm5bOTl2NkK5O|U>
DU145NIXZVFRHfW6ldHnvckBCe3OjeR?=NFKz[VgxNjFizszNNGfGS2k2KGh?M2TYcmROW09?MlG3TY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2=MnrjNVk1PjJ7N{W=
PC3MoexT4lv[XOnIFHzd4F6MorvNE4yKM7:TR?=M4LkeFUhcA>?NEGxWIdFVVORMVzJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6PM4r2clE6PDZ{OUe1
DU145NHzRZ|VMcW6jc3WgRZN{[Xl?MYCwMlEh|ryPMVu1JIg>NGjCb3NFVVORMVPJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=MWmxPVQ3Ojl5NR?=
PC3MXHLbY5ie2ViQYPzZZk>MmjGNE4yKM7:TR?=NY\GTpI3PSCqNWD0NXI5TE2VTx?=M1n4TmlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?M1PiU|E6PDZ{OUe1
DU145MVPLbY5ie2ViQYPzZZk>NUHDeo5mOC5zIN88US=>M3;SelUhcA>?MVfEUXNQNF7uUY9KdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?=M2fwcFE6PDZ{OUe1
Huh7NWfROo9ISW62aY\pdoFtKEG|c3H5MnrvNk42KM7:TR?=NVn6fGxIPCCmYYnzMnXPSG1UVw>?NEHsUGhKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2=M2TsTVE4OzZyNke2
C6/36MmfvRY51cX[rcnHsJGF{e2G7NX3WbVFYOi53IN88US=>Mkj0OEBl[Xm|NHTYZWpFVVORNF6wclZKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWPNVrUO|FmOTd|NkC2O|Y>
U937NEjpNmdHfW6ldHnvckBCe3OjeR?=NH7MT3MyKM7:TR?=NGXKT5cyKGh?MXPEUXNQMW\S[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>?NWLvd4ZGOTd4OESwPVk>
U937MU\GeY5kfGmxbjDBd5NigQ>?NFvsTFEyKM7:TR?=M2LOclEhcA>?NYXTRYJRTE2VTx?=M2TPcnJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{M3\SbVE4Pjh2MEm5
murine mast cellNX3wRm1TTnWwY4Tpc44hSXO|YYm=MnvxNUDPxE1?MYeyOEBpMXHEUXNQMkjRTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1?NWi0TmVjOTd4OESwPVk>
BV-173MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[4SHBoUUN3ME2wMlAxODByMEGwPUDPxE1?NUDSfHJLW0GQR1XS
K-562NF3vOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;0[GlEPTB;MD6wNFAxODB{Nk[g{txOM3;ybnNCVkeHUh?=
BL-70NE\LVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnGUVJpUUN3ME2wMlAxODByMEiyNkDPxE1?M32wTHNCVkeHUh?=
EM-2M{HZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfwTWM2OD1yLkCwNFAxOTB6IN88US=>MoHOV2FPT0WU
LAMA-84M32y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYO5dlJmUUN3ME2wMlAxODByM{KxJO69VQ>?NV;zTpc3W0GQR1XS
MEG-01M4\BNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjaTWM2OD1yLkCwNFAxQThizszNNXG2W3M1W0GQR1XS
EoL-1-cellNXrjb5JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rHbWlEPTB;MD6wNFAxOTNzIN88US=>M1[zRnNCVkeHUh?=
CTV-1NFnkSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3r6WmlEPTB;MD6wNFAxPDB2IN88US=>NIH4RYlUSU6JRWK=
TE-15MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvaTWM2OD1yLkCwOVg6KM7:TR?=NIixVXlUSU6JRWK=
NOS-1NGjVbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7CenNsUUN3ME2wMlAxPjF|IN88US=>NUnVWpdxW0GQR1XS
D-336MGMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\vc21KSzVyPUCuNFA3OyEQvF2=Ml3sV2FPT0WU
LB1047-RCCM4q0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX0eYRnUUN3ME2wMlAxQTh7IN88US=>NFHrTGNUSU6JRWK=
LB996-RCCNXPQ[FNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTJfHhHUUN3ME2wMlAxQTlzIN88US=>MlPZV2FPT0WU
SW982NVTFc2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLMfGdKSzVyPUCuNFEyOTVizszNNV\wRpd1W0GQR1XS
TK10MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD3TWM2OD1yLkCxNVc1KM7:TR?=M3LoOXNCVkeHUh?=
A704MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1f4[2lEPTB;MD6wNVQ6OSEQvF2=M1X3OnNCVkeHUh?=
TE-8M3vHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYS4Z4hSUUN3ME2wMlAyPTd4IN88US=>NF\0WnNUSU6JRWK=
DOHH-2NV3oRpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjFc|lKSzVyPUCuNFE4OTlizszNM1O5WXNCVkeHUh?=
HOP-62MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4P5fGlEPTB;MD6wNVg{PCEQvF2=NXr3V2V5W0GQR1XS
TE-12NFToZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwMEG4OlEh|ryPM2XOfnNCVkeHUh?=
KGNNF;vdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHVTWM2OD1yLkCxPVQzKM7:TR?=NHH5doJUSU6JRWK=
NCI-H1648NX7sRWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7UTWM2OD1yLkCyNFEyKM7:TR?=NHnxZoJUSU6JRWK=
OS-RC-2MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPjZ4VKSzVyPUCuNFIxOyEQvF2=NEO1N2xUSU6JRWK=
GB-1NYnuNWVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vIWGlEPTB;MD6wNlE2PyEQvF2=MoHpV2FPT0WU
RXF393M3jZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mor6TWM2OD1yLkCyN|U4KM7:TR?=MWHTRW5ITVJ?
LC-2-adMnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMEK1PFYh|ryPMlPMV2FPT0WU
KS-1MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TNTWlEPTB;MD6wNlc{KM7:TR?=M4ezWHNCVkeHUh?=
ETK-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDtSJdKSzVyPUCuNFI5OzJizszNM33GZnNCVkeHUh?=
SW954NWH3WXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{D1T2lEPTB;MD6wNlkzPyEQvF2=M1vNfXNCVkeHUh?=
BeckerNFnDS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHVe5h3UUN3ME2wMlA{ODB|IN88US=>MWrTRW5ITVJ?
MZ1-PCMkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVX4R2lDUUN3ME2wMlA{OTF7IN88US=>MYfTRW5ITVJ?
ES6MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTBwMEOxPVMh|ryPM1TScXNCVkeHUh?=
KURAMOCHIM3rrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rscmlEPTB;MD6wN|Q5PyEQvF2=MYTTRW5ITVJ?
CGTH-W-1NEn0c41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfqRnJyUUN3ME2wMlA{PTR6IN88US=>NVzTPJU{W0GQR1XS
VA-ES-BJNEDldohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWm1do5oUUN3ME2wMlA{QTB{IN88US=>Ml:xV2FPT0WU
LXF-289M2DzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHKyNo9KSzVyPUCuNFM6PTZizszNNWP0flJKW0GQR1XS
MPP-89NH;UOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTBwMESwOFkh|ryPM2D6fHNCVkeHUh?=
SW872MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7LPWdKSzVyPUCuNFQyPjFizszNNXP5blVZW0GQR1XS
SNB75NYX3e5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETufVlKSzVyPUCuNFQ1OzVizszNNYDLbZlKW0GQR1XS
PSN1Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwMES0O|Qh|ryPMUjTRW5ITVJ?
LB831-BLCMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmSyTWM2OD1yLkC0OlA6KM7:TR?=MYjTRW5ITVJ?
MFH-inoNHXPbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\aTWM2OD1yLkC0O|I1KM7:TR?=MmfpV2FPT0WU
TGBC24TKBMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGezW2ZKSzVyPUCuNFQ4PjFizszNMVHTRW5ITVJ?
A388NEG0T3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXr2NZhyUUN3ME2wMlA2ODl3IN88US=>M{Dw[nNCVkeHUh?=
BB30-HNCNE[0O3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXkelVjUUN3ME2wMlA2PDN5IN88US=>NFrPTnBUSU6JRWK=
GI-ME-NMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIC2XmpKSzVyPUCuNFYyOThizszNM2q2cnNCVkeHUh?=
TGBC1TKBMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTmTWZKSzVyPUCuNFYyPjRizszNNG[5fVZUSU6JRWK=
TE-10NFPFeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrSNlRKSzVyPUCuNFY{PTdizszNNHfPbndUSU6JRWK=
A498NHLZfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HxdGlEPTB;MD6wO|I5PCEQvF2=NVfhfFdjW0GQR1XS
TE-11M1PjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NID2UHNKSzVyPUCuNFc5PThizszNMn63V2FPT0WU
BB65-RCCM3u3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfYTWM2OD1yLkC4NlI4KM7:TR?=NIm2V4tUSU6JRWK=
C2BBe1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\wZ2pKSzVyPUCuNFg{ODhizszNM124SXNCVkeHUh?=
NCI-H747NHzVbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\nRWlEPTB;MD6wPFM3OiEQvF2=NXvaUG1QW0GQR1XS
IST-MES1NHG0[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PMWGlEPTB;MD6wPFU2OiEQvF2=NWrXXGhNW0GQR1XS
KALS-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTBwMEm0PUDPxE1?MmHWV2FPT0WU
GCIYMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHhWlBZUUN3ME2wMlA6PjV4IN88US=>M3TXb3NCVkeHUh?=
RL95-2MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jJZmlEPTB;MD6xNFM5KM7:TR?=NIPTR21USU6JRWK=
TE-1M{PpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XqUmlEPTB;MD6xNFU1KM7:TR?=M3fNd3NCVkeHUh?=
NCI-H1355MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1j4XGlEPTB;MD6xNVAzQCEQvF2=NFrYTpNUSU6JRWK=
SW962M1mwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTBwMUGyPVIh|ryPMXLTRW5ITVJ?
KLEM1jmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XnWGlEPTB;MD6xNVMyPyEQvF2=M1ftXHNCVkeHUh?=
MC116MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnJ[I97UUN3ME2wMlEyPDFizszNMV\TRW5ITVJ?
NMC-G1NUTHfWdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTBwMUG2NFYh|ryPNE\QdnlUSU6JRWK=
KU812NUHtcWE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMUG4PFMh|ryPMWXTRW5ITVJ?
COLO-829NHj0eFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnkTWM2OD1yLkGyNlE{KM7:TR?=NYHYe4xWW0GQR1XS
NTERA-S-cl-D1MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXxTWM2OD1yLkGyNlg{KM7:TR?=MYHTRW5ITVJ?
IST-MEL1M132Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TiSGlEPTB;MD6xN|Q2KM7:TR?=NGThdmZUSU6JRWK=
MLMANYK4SJhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LTXWlEPTB;MD6xOFA{OiEQvF2=M4H2dXNCVkeHUh?=
LS-123NF:zdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLoTWM2OD1yLkG0NFY1KM7:TR?=M4jFXHNCVkeHUh?=
LB2518-MELM3\vbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrNTWM2OD1yLkG0NVYzKM7:TR?=MlG4V2FPT0WU
NB69NWnuS|NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIT6W3NKSzVyPUCuNVQ1OzZizszNNVHYVnZUW0GQR1XS
8-MG-BAMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PYbWlEPTB;MD6xOVQ2QCEQvF2=Mln3V2FPT0WU
K5NYnCeIFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DNPWlEPTB;MD6xOlQ5QSEQvF2=NVn5cWVPW0GQR1XS
KINGS-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmi1TWM2OD1yLkG2OlY3KM7:TR?=M1jkO3NCVkeHUh?=
SF268Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTBwMUe0NFQh|ryPNEDlVJZUSU6JRWK=
PF-382NFrzcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPBTWM2OD1yLkG3Olc5KM7:TR?=NVnZSFFbW0GQR1XS
SH-4Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LxOGlEPTB;MD6xPFQyOyEQvF2=MlPYV2FPT0WU
NALM-6MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HnWGlEPTB;MD6xPVI6PSEQvF2=NFfvepRUSU6JRWK=
CP66-MELNVvi[JBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmezTWM2OD1yLkG5OVMyKM7:TR?=M1TzZXNCVkeHUh?=
697MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTHR2k{UUN3ME2wMlE6QTh5IN88US=>MXHTRW5ITVJ?
CP67-MELM1jaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvTfJhiUUN3ME2wMlIxPDh6IN88US=>MkK2V2FPT0WU
DSH1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTBwMkSwNFEh|ryPMVPTRW5ITVJ?
HCE-4Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWf5RndZUUN3ME2wMlI3PDN7IN88US=>NETBWGtUSU6JRWK=
MZ2-MELMoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknHTWM2OD1yLkK4OVM4KM7:TR?=MVfTRW5ITVJ?
BL-41Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLCTldJUUN3ME2wMlI6OTJ|IN88US=>NHzUcFhUSU6JRWK=
HUTU-80Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEH1WoFKSzVyPUCuN|E1OiEQvF2=NGD4WJNUSU6JRWK=
LOXIMVIMlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTBwM{G1NFMh|ryPMXrTRW5ITVJ?
no-10NWTN[JBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWW4cZRtUUN3ME2wMlMyQTNzIN88US=>MWDTRW5ITVJ?
KARPAS-422NFLXR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHtSHJ7UUN3ME2wMlM{QTl5IN88US=>M13pcHNCVkeHUh?=
SW684MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwM{S5PEDPxE1?MVLTRW5ITVJ?
SF126M2fs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwM{W0NUDPxE1?MUDTRW5ITVJ?
D-263MGMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTLTWM2OD1yLkO2NlI1KM7:TR?=MUTTRW5ITVJ?
OVCAR-4M2TuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1T0N2lEPTB;MD6zO|Q{OyEQvF2=MUjTRW5ITVJ?
BB49-HNCMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DEVWlEPTB;MD6zPFU6QSEQvF2=NY[4OFJtW0GQR1XS
ONS-76NEHJfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLRdpFKSzVyPUCuOFI6PTFizszNNIPUO5dUSU6JRWK=
MZ7-melNUTre5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXXWZh[UUN3ME2wMlQ4QTFzIN88US=>NET2N2FUSU6JRWK=
RCC10RGBM3[wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTyTGo{UUN3ME2wMlQ6OTFizszNNWTZXFFTW0GQR1XS
BOKUMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXS[lNKSzVyPUCuOFkyOzNizszNM3nndXNCVkeHUh?=
no-11MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPOdmo2UUN3ME2wMlUxOjJ6IN88US=>MoTXV2FPT0WU
IST-SL2NISyPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlftTWM2OD1yLkWwN|AzKM7:TR?=M3zDV3NCVkeHUh?=
RKONVvFXohbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTBwNUK5OlYh|ryPMVXTRW5ITVJ?
HT-144M3v3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\w[GNQUUN3ME2wMlU{PjB7IN88US=>NIXYemVUSU6JRWK=
NCI-H446NFHYUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwNkK3OkDPxE1?NGP4flJUSU6JRWK=
QIMR-WILNGnhUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zMOmlEPTB;MD63NFYzQSEQvF2=MXXTRW5ITVJ?
MHH-PREB-1MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHYeGxKSzVyPUCuO|Q1PjlizszNNGrJUGxUSU6JRWK=
EW-16NVTuNpFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHtXJdKSzVyPUCuO|YyPzhizszNNYX3Tlc5W0GQR1XS
EW-24MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\YOFQ3UUN3ME2wMlc5OTZ3IN88US=>NXTYS3I6W0GQR1XS
LB373-MEL-DMoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwOEK1NFgh|ryPNUT2TlV1W0GQR1XS
TE-9MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYH5RZNuUUN3ME2wMlg4PTN{IN88US=>M4XZO3NCVkeHUh?=
A3-KAWM1Hh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTrPXFZUUN3ME2wMlk5PDV{IN88US=>NX7WbFJtW0GQR1XS
A101DNEfISZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPoUYZKSzVyPUGuNFMxPDNizszNNUf3SVk2W0GQR1XS
OCUB-MMmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTsTWM2OD1zLkC0OFEzKM7:TR?=NWPwXmJWW0GQR1XS
ES4NUDUV2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIKzfldKSzVyPUGuNFUyPDVizszNM{DEfnNCVkeHUh?=
TE-6MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDqNVd3UUN3ME2xMlIyOjJ4IN88US=>NHP5S|ZUSU6JRWK=
D-502MGNXTpN4FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXxVFBQUUN3ME2xMlI{Ozd4IN88US=>M3XJN3NCVkeHUh?=
KNS-42MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\4OJJZUUN3ME2xMlI1PDF{IN88US=>NFvHRpVUSU6JRWK=
SNU-C2BM2rQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPLZ5dxUUN3ME2xMlMxPTh7IN88US=>Mk\rV2FPT0WU
NCI-H1838Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fCVmlEPTB;MT6zNFc{OyEQvF2=NUXXTVlnW0GQR1XS
NKM-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTFwM{C4OVkh|ryPMVnTRW5ITVJ?
GI-1NYjPeZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTFwM{[yNkDPxE1?NXjUTpdUW0GQR1XS
NB5NVjIbHFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTQZnZNUUN3ME2xMlM6QDJ5IN88US=>NUSzTWd4W0GQR1XS
CAS-1NYfMPYFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjVfHdKSzVyPUGuOFA6QTJizszNMVHTRW5ITVJ?
HCE-TM4fHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTXTWM2OD1zLkW2O|E1KM7:TR?=NUHpdIhEW0GQR1XS
SBC-1MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf1TWM2OD1zLkW3PVg1KM7:TR?=MnLSV2FPT0WU
JiyoyeP-2003M1O3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;0TWM2OD1zLkezOFY3KM7:TR?=M4LLTHNCVkeHUh?=
TE-5M1rmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HsVGlEPTB;MT63PVE{QSEQvF2=NHTr[o1USU6JRWK=
CANNUG4bGN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPWZ|U4UUN3ME2xMlgzOjV{IN88US=>NU\xV2NlW0GQR1XS
SK-UT-1NH3abVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJwMU[2PVMh|ryPMXnTRW5ITVJ?
JVM-2NEP6UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrsOnRFUUN3ME2yMlM3Ojh2IN88US=>NIfGOllUSU6JRWK=
LB771-HNCNHnwOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DoXmlEPTB;Mj61O|U2OSEQvF2=MWfTRW5ITVJ?
NCCITNVjUdIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\TTWM2OD1{Lki2OlE3KM7:TR?=NUm0Sm0xW0GQR1XS
NCI-H2126NXq1RY1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV25[nNuUUN3ME2yMlg4PTV{IN88US=>NXrQeFdmW0GQR1XS
Calu-6M{OyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HJ[WlEPTB;Mz6wOVc1OSEQvF2=M3;IOXNCVkeHUh?=
SK-LMS-1NFLYbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXuySItuUUN3ME2zMlEyQDh4IN88US=>MX\TRW5ITVJ?
ARH-77M2L4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LoZ2lEPTB;Mz60OlkyPSEQvF2=MneyV2FPT0WU
NB17NED0[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVO4OHVwUUN3ME2zMlY{QDR5IN88US=>MYrTRW5ITVJ?
A253NYrwSXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTNwN{OyOFYh|ryPMn7sV2FPT0WU
OPM-2MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zpSGlEPTB;ND6yO|Y5PSEQvF2=MmTBV2FPT0WU
MV-4-11MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4G0eWlEPTB;ND6zOlQ2PCEQvF2=M4Xhe3NCVkeHUh?=
SRM1zZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmWzTWM2OD12LkS5PVU1KM7:TR?=M17JVHNCVkeHUh?=
KG-1NWHnfFdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjGZ2VPUUN3ME20MlYxQDR3IN88US=>Mnj4V2FPT0WU
OCI-AML2M{LSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTVwOE[xOVQh|ryPMX\TRW5ITVJ?
D-247MGM4DxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\NTWM2OD14LkGyOVE6KM7:TR?=M3TuNnNCVkeHUh?=
DJM-1M2LBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTZwNEi1OVgh|ryPM3zvfHNCVkeHUh?=
RPMI-6666NWDIcoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NULPSVkxUUN3ME23MlI4ODZ5IN88US=>MoPXV2FPT0WU
KARPAS-45NF25fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jxXGlEPTB;Nz61NVY4OSEQvF2=MVHTRW5ITVJ?
LP-1M4fIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWGzXJdrUUN3ME23MlU1Pzh{IN88US=>NVP3Oo9yW0GQR1XS
RS4-11MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrGSIU6UUN3ME23MlY2Pzh5IN88US=>MUHTRW5ITVJ?
DU-4475MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoSyTWM2OD16LkKxOlUzKM7:TR?=NWKzcmRLW0GQR1XS
MONO-MAC-6NGjMWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRThwMkewOlYh|ryPMUHTRW5ITVJ?
NCI-SNU-16Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1z0eGlEPTB;OD61OlEzQCEQvF2=MlW5V2FPT0WU
SJSA-1NGjqSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{S3bmlEPTB;OD63NlgxPSEQvF2=MXXTRW5ITVJ?
MMAC-SFM134b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TW[2lEPTB;OD63PVMxPyEQvF2=MX;TRW5ITVJ?
SK-NEP-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzLTWM2OD16Lki5NVU2KM7:TR?=MX7TRW5ITVJ?
J-RT3-T3-5NW\LPJN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfQTYVKSzVyPUiuPVY2OjlizszNMV;TRW5ITVJ?
SKM-1M4\3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTlwMEG3N|Qh|ryPM3zwN3NCVkeHUh?=
LB2241-RCCMkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\0TWM2OD17LkCyNFEzKM7:TR?=M1rS[HNCVkeHUh?=
SIG-M5M2fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTlwMEK0PVMh|ryPNH24e2xUSU6JRWK=
EVSA-TM2Hx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDPXZhKSzVyPUmuNlc4QTNizszNMn6yV2FPT0WU
GT3TKBNVPkfVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTlwM{W1OFYh|ryPM1n4THNCVkeHUh?=
NB6NWK4XlNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVL6SnR1UUN3ME25MlkzOjV7IN88US=>MU\TRW5ITVJ?
EHEBNXPyPW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vNdGlEPTB;MUCuNFY2PiEQvF2=M1;kfnNCVkeHUh?=
HELNV\hcHRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzKTWM2OD1zMD60O|c3KM7:TR?=M2SxVnNCVkeHUh?=
ALL-PONYPScmVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvHTWM2OD1zMD63PVM5KM7:TR?=NV;BdoR7W0GQR1XS
TGWNUTtbIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXLTWM2OD1zMT6yPFI5KM7:TR?=NU\P[pU2W0GQR1XS
BC-3MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\ETWM2OD1zMj6xNVM5KM7:TR?=M33VcnNCVkeHUh?=
IA-LMMmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTF{LkS0OFUh|ryPNHW1NlhUSU6JRWK=
UACC-257MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml30TWM2OD1zMj65NVk5KM7:TR?=MnHIV2FPT0WU
KP-N-YSMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTF{LkmyPFMh|ryPNES1RYFUSU6JRWK=
RajiNYTUPY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTF|Lke0PVch|ryPM4rufnNCVkeHUh?=
SF539MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjMbYgyUUN3ME2xN{45PTV5IN88US=>NIHWc2dUSU6JRWK=
DMS-153M3T6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jnOGlEPTB;MUSuNFAzQCEQvF2=M4rDTXNCVkeHUh?=
L-540NYPjXml[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTF3LkC2O|Ih|ryPMnLHV2FPT0WU
MN-60MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTF3LkG5O|kh|ryPNFvWbmlUSU6JRWK=
RPMI-8866Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTF5LkS0OVQh|ryPMl7QV2FPT0WU
NCI-H510AMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjz[4NKSzVyPUG5MlM6PzNizszNM{PSe3NCVkeHUh?=
NB13NVn0flE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTzTWM2OD1zOT60PFc4KM7:TR?=Ml:zV2FPT0WU
HAL-01NXLJNpBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTF7Lke1OFMh|ryPNGjRW2NUSU6JRWK=
NCI-H720NU\nUnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrCZlhKSzVyPUKwMlI4OzNizszNMkXTV2FPT0WU
REHNUPrNpVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHP4dHRKSzVyPUKwMlY{PTdizszNNHTHUplUSU6JRWK=
KNS-81-FDM3\UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\qbWhVUUN3ME2yN{4yPDZizszNMmTwV2FPT0WU
HC-1NXn5[YR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJ2LkW1OVEh|ryPNGLsVY9USU6JRWK=
NCI-H2141M1Xwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTJ2Lke3OVQh|ryPM332PHNCVkeHUh?=
MOLT-4MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHn5eG5KSzVyPUK2MlY4PTNizszNNIfEVXlUSU6JRWK=
OMC-1NGG0O3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHu4b2dKSzVyPUK3MlE1OjJizszNNHrMUoVUSU6JRWK=
LC-1FM4LnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jYfWlEPTB;MkeuN|I1PSEQvF2=MYrTRW5ITVJ?
NCI-H1304MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvOTWM2OD1{OD6xOlI5KM7:TR?=NYL6R3JpW0GQR1XS
BC-1NHjqTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXWTWM2OD1{OD62OVEh|ryPMWPTRW5ITVJ?
NCI-H64M1L4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF24PW5KSzVyPUK5MlYzPTNizszNMmHkV2FPT0WU
MOLT-16M3TGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v5T2lEPTB;MkmuOlI6OiEQvF2=NX\PeIJ5W0GQR1XS
U-87-MGMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoKyTWM2OD1|MD63OlYh|ryPNU\RO2JQW0GQR1XS
GAKMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTNzLkK2PFYh|ryPM{jVZ3NCVkeHUh?=
ES8NWH5[ZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXwTWM2OD1|Mj6xNlUzKM7:TR?=MnXOV2FPT0WU
HCC1599MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTN{LkOzNlUh|ryPNXL5THBpW0GQR1XS
EB-3NW\IXmxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTlTWM2OD1|ND6zNVE4KM7:TR?=NVvsR21HW0GQR1XS
HCC1187NG[5bHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHafYdKSzVyPUO1MlgxPTJizszNNVntRXQyW0GQR1XS
SK-PN-DWNEjIfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTN4LkG5OFMh|ryPM1zRe3NCVkeHUh?=
JVM-3NF;3RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTN5LkKzN|gh|ryPNIn3bY1USU6JRWK=
HCC2157NIPFVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3SyW2lEPTB;M{euPVk1PiEQvF2=NYrsPYc1W0GQR1XS
A4-FukMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{S1NWlEPTB;M{iuNVAxQSEQvF2=NFXIN3NUSU6JRWK=
COR-L279NF60UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTRyLkK4OVEh|ryPMWDTRW5ITVJ?
DELMknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvFXYlsUUN3ME20NU46ODh4IN88US=>MVXTRW5ITVJ?
NCI-H1395MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVztcHg2UUN3ME20Nk4xOTZ|IN88US=>M2jSTnNCVkeHUh?=
MHH-NB-11NIjiWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\QTWM2OD12Mz6wPFE5KM7:TR?=MULTRW5ITVJ?
NCI-H2107MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHT4SIRKSzVyPUSzMlQ5PDZizszNM3\XfXNCVkeHUh?=
NEC8M{fCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXftXG5IUUN3ME20OE4{OzZizszNM{f3RnNCVkeHUh?=
COLO-684MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L1VWlEPTB;NE[uNlI2QCEQvF2=NYH1fVNZW0GQR1XS
LS-411NNEjORZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XJPGlEPTB;NEiuOFc1QCEQvF2=MlLxV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

Cell Assay:

[1]

Cell lines Ba/F3 cell lines
Concentrations ~32 nM
Incubation Time 72 hours
Method

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

Animal Study:

[3]

Animal Models EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
Formulation DMSO
Dosages 30 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] O'Hare T, et al. Cancer Res. 2005, 65(11), 4500-4505.

[2] Shah NP, et al. Blood, 2006, 108(1), 286-291.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT02815059 Not yet recruiting Acute Lymphoblastic Leukemia University of Utah|Janssen, LP August 2016 Phase 1
NCT02819804 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblast  ...more B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia Northwestern University|National Cancer Institute (NCI) July 2016 Phase 1
NCT02848131 Recruiting Chronic Kidney Disease Mayo Clinic July 2016 Phase 2
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto June 2016 Phase 2

view more

Chemical Information

Download Dasatinib SDF
Molecular Weight (MW) 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms BMS-354825
Solubility (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

Frequently Asked Questions

  • Question 1
    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

    Answer: Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us